Kejadian Demam Neutropenia pada Pasien Kanker Payudara setelah Menerima Regimen Kemoterapi TAC-G-CSF dan FAC di RSUP Dr. Hasan Sadikin Bandung
Abstract
Demam neutropenia merupakan efek samping yang sering terjadi setelah kemoterapi. Demam neutropenia dapat menyebabkan penundaan dosis kemoterapi sehingga dapat mengurangi efektivitas terapi. Kejadian demam neutropenia setelah kemoterapi dapat dicegah dengan pemberian Granulocyte-colony Stimulating Factor (G-CSF). Regimen kemoterapi yang digunakan dapat memengaruhi kejadian demam neutropenia. Selain itu, usia, stadium kanker, riwayat kemoterapi dan kadar hemoglobin sebelum kemoterapi merupakan faktor risiko demam neutropenia setelah kemoterapi. Penelitian ini bertujuan untuk mengetahui perbandingan kejadian demam neutropenia regimen Dosetaksel, Doksorubisin, Siklofosfamid (TAC) dengan profilaksis primer G-CSF dan regimen Fluorourasil, Doksorubisin, Siklofosfamid (FAC) pada pasien kanker payudara di RSUP Dr. Hasan Sadikin Bandung periode Januari 2017–Juni 2019. Desain penelitian adalah cross sectional uji dua populasi. Jumlah sampel sebanyak 61 regimen TAC-G-CSF dan 102 regimen FAC. Kejadian demam neutropenia dianalisis menggunakan Chi-Square, Kruskal Wallis dan regresi logistik. Hasil penelitian menunjukkan kejadian demam neutropenia setelah kemoterapi pada regimen TAC dengan profilaksis primer G-CSF lebih tinggi dibanding pada regimen FAC. Usia, stadium kemoterapi, riwayat kemoterapi dan kadar hemoglobin sebelum kemoterapi secara statistik tidak signifikan memengaruhi kejadian demam neutropenia setelah kemoterapi.
Kata kunci: Demam neutropenia, FAC, granulocyte-colony stimulating factor (G-CSF), regimen kemoterapi, TAC
The Incidence of Febrile Neutropenia in Patients with Breast Cancer after Receiving TAC-G-CSF and FAC Chemotherapy Regimen at Dr. Hasan Sadikin Hospital Bandung
Abstract
Febrile neutropenia is a common side effect of chemotherapy, and it reduces the effectiveness of therapy through the delay in chemo doses. Granulocyte-colony Stimulating Factor (G-CSF) is administered to prevent its incidence. The chemotherapy regimen affects the incidence of febrile neutropenia. Risk factors for febrile neutropenia include; age, stage of cancer, history of chemotherapy and pre-chemotherapy hemoglobin level. The purpose of this study was to compare the incidence of febrile neutropenia between Docetaxel, Doxorubicin, Cyclophosphamide (TAC) regimen with G-CSF primary prophylaxis and Fluorouracil, Doxorubicin, Cyclophosphamide (FAC) regimen in patients with breast cancer at Dr. Hasan Sadikin Hospital Bandung at the period of January 2017–June 2019. The cross-sectional study design of two populations was used. The sample consisted of 61 TAC and 102 FAC regimens. The Chi-Square, Kruskal Wallis, and logistic regression were used to analyze the incidence of febrile neutropenia. The results showed that the incidence of post-chemotherapy febrile neutropenia in TAC regimen with G-CSF primary prophylaxis was higher compared with FAC regimen. Furthermore, the risk factors had no statistical influence on the incidence of febrile neutropenia.
Keywords: Chemotherapy regimen, FAC, febrile neutropenia, granulocyte-colony stimulating factor (G-CSF), TAC
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492
Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, et al. Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract. 2015;11(1):47–54. doi: 10.1200/JOP.2014.001492
Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med. 2010;363(23):2200–10. doi: 10.1056/NEJMoa0910320
Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011;29(29):3877–84. doi: 10.1200/JCO.2010.28.5437
Furuya Y. Early neutropenia on day 8 treated with adjuvant Docetaxel-based chemotherapy in early breast cancer patients: Putative mechanisms within the neutrophil pool system. PLoS One. 2019;14(4):e0215576. doi: 10.1371/journal.pone.0215576
Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014;90(3):190–9. doi: 10.1016/j.critrevonc.2013.12.006
Budiana, ING, Febiani M. Febrile neutropenia pada pasien pascakemoterapi. Indones J Cancer. 2017;11(2):281–5. doi: 10.33371/ijoc.v11i2.505
Lee J, Lee JE, Kim Z, Han SW, Hur SM, Kim SY, et al. Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy. Ann Surg Treat Res. 2018; 94(5):223–8. doi: 10.4174/astr.2018.94.5.223
Truong J, Lee EK, Trudeau ME, Chan KKW. Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: A systematic review and meta-analysis. Ann Oncol. 2016;27(4):608–18. doi: 10.1093/annonc/mdv619
Rosary R, Sjakti HA. Penggunaan granulocyte colony-stimulating factor pada pasien tumor padat yang mengalami neutropenia. Sari Pediatri. 2016;11(6):428. doi: 10.14238/sp11.6.2010.428-33
Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, et al. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol. 2013;31(34):4290–6. doi: 10.1200/JCO.2012.44.6229
Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Oncol Pract. 2013;31(6):794–810. doi: 10.1200/JCO.2012.45.8661.
Park KH, Lee S, Park JH, Kang SY, Kim HY, Park IH, et al. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer. Support Care Cancer. 2017;25(2):505–11. doi: 10.1007/s00520-016-3429-2
Kim HS, Lee SY, Kim JW, Choi YJ, Park IH, Lee KS, et al. Incidence and predictors of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy in Korea. Oncol. 2016;91(5):274–82. doi: 10.1159/000449226
DOI: https://doi.org/10.15416/ijcp.2021.10.1.1
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
